M1/M2 polarization of Lyz2Cre+ or C57Bl/6 BMDMs yield unique phenotypes when polarized in the presence/absence of EGFR inhibitor Erlotinib

We report the gene expression (obtained by next generation RNAseq) of bone marrow derived macrophages from Lyz2Cre+ or C57Bl/6 mice that have been polarized to an M1 or M2 phenotype in the presence of absence of EGFR inhibitor, Erlotinib. This study provides data on how M1 and M2 BMDMs differ in their overall gene expression profiles in mice as well as how gene expression is influenced by EGFR inhibition during polarization. Overall design: BMDMs derived from Lyz2Cre+ or C57Bl/6 mice were treated with LPS (100ng/ml)+IFNg (50ng/ml) to achieve an M1 phenotype and with IL-4 (10ng/ml)+IL13 (10ng/ml) to achieve an M2 phenotype. BMDMs receiving erlotinib treatment were given erlotinib (1uM) at time of M1/M2 polarization